MTOR and renal fibrosis: By integrated network pharmacology, transcriptomic analysis, and pharmacological assessment, we predicted and confirmed that the therapeutic mechanism of YSPDP in addressing 5/6 SNx-induced renal fibrosis may involve inhibition of the PI3K/AKT/mTOR signaling pathway.